



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Ruxience

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
IA/0012	A.6 - Administrative change - Change in ATC Code/ATC Vet Code	12/12/2022		SmPC	
II/0011	B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting	01/09/2022		Annex II	The section A in Annex II (Manufacturers of the biological active substance and manufacturers responsible for batch release) has been updated as follows:

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	material [-] used in the manufacture of a biological/immunological product				Pfizer Ireland Pharmaceuticals Grange Castle Business Park Clondalkin, Dublin 22 Ireland
PSUSA/2652/202111	Periodic Safety Update EU Single assessment - rituximab	23/06/2022	24/08/2022	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) for PSUSA/2652/202111.
IB/0009	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	07/01/2022	n/a		
IB/0008	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	23/09/2021	24/08/2022	SmPC and PL	
PSUSA/2652/202011	Periodic Safety Update EU Single assessment - rituximab	24/06/2021	20/08/2021	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2652/202011.
IB/0007	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	15/04/2021	20/08/2021	PL	
IB/0004	B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or	30/07/2020	20/08/2021	SmPC	

	reconstitution (supported by real time data)				
IB/0003/G	<p>This was an application for a group of variations.</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p>	08/07/2020	31/07/2020	SmPC, Labelling and PL	
II/0001	<p>to extend the validated hold times of the virus retaining filtration (VRF) load and the ultrafiltration/diafiltration (UF/DF) load during active substance manufacture.</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance</p>	25/06/2020	n/a		

	which may have a significant impact on the medicinal product and is not related to a protocol				
IA/0002	B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor changes to an approved test procedure	29/05/2020	n/a		